LXEO 8-K
Lexeo Therapeutics, Inc. (LXEO)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 26, 2025, Lexeo Therapeutics, Inc. (the “Company”) held its virtual 2025 Annual Meeting of Stockholders (the “Annual Meeting”) exclusively online via live webcast. The stockholders voted on the following proposals at the Annual Meeting:
Proposal 1. Election of Class II Directors
The Company’s stockholders elected the persons listed below as Class II Directors, to serve until the Company’s 2028 Annual Meeting of Stockholders and until their respective successors are elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows:
|
FOR |
WITHHELD |
BROKER NON-VOTE |
Steven Altschuler, M.D. |
19,800,126 |
2,775,771 |
5,374,056 |
Reinaldo Diaz |
19,986,796 |
2,589,101 |
5,374,056 |
Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm
The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The final voting results are as follows:
|
FOR |
AGAINST |
ABSTAIN |
|
27,929,327 |
18,858 |
1,768 |
For more information about the foregoing proposals, see the Proxy Statement as filed with the Securities and Exchange Commission (the "SEC") on April 28, 2025, as supplemented by the additional definitive proxy soliciting materials filed with the SEC on June 5, 2025.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Lexeo Therapeutics, Inc. |
|
|
|
|
Date: |
June 30, 2025 |
By: |
/s/ R. Nolan Townsend |
|
|
|
R. Nolan Townsend, Chief Executive Officer |